Annual EBITDA
-$10.94 M
-$20.00 M-220.75%
December 31, 2023
Summary
- As of February 7, 2025, VNDA annual EBITDA is -$10.94 million, with the most recent change of -$20.00 million (-220.75%) on December 31, 2023.
- During the last 3 years, VNDA annual EBITDA has fallen by -$41.05 million (-136.35%).
- VNDA annual EBITDA is now -124.31% below its all-time high of $45.01 million, reached on December 31, 2021.
Performance
VNDA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.03 M
-$855.00 K-10.45%
September 30, 2024
Summary
- As of February 7, 2025, VNDA quarterly EBITDA is -$9.03 million, with the most recent change of -$855.00 thousand (-10.45%) on September 30, 2024.
- Over the past year, VNDA quarterly EBITDA has dropped by -$2.02 million (-28.84%).
- VNDA quarterly EBITDA is now -169.05% below its all-time high of $13.08 million, reached on June 30, 2021.
Performance
VNDA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$30.16 M
-$3.62 M-13.63%
September 30, 2024
Summary
- As of February 7, 2025, VNDA TTM EBITDA is -$30.16 million, with the most recent change of -$3.62 million (-13.63%) on September 30, 2024.
- Over the past year, VNDA TTM EBITDA has dropped by -$9.53 million (-46.21%).
- VNDA TTM EBITDA is now -164.40% below its all-time high of $46.83 million, reached on September 30, 2021.
Performance
VNDA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VNDA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -220.8% | -28.8% | -46.2% |
| 3 y3 years | -136.3% | -28.8% | -46.2% |
| 5 y5 years | -144.3% | -28.8% | -46.2% |
VNDA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -124.3% | at low | -196.7% | at low | -167.0% | at low |
| 5 y | 5-year | -124.3% | at low | -169.1% | at low | -164.4% | at low |
| alltime | all time | -124.3% | +85.1% | -169.1% | +65.1% | -164.4% | +60.7% |
Vanda Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.03 M(+10.5%) | -$30.16 M(+13.6%) |
| Jun 2024 | - | -$8.18 M(+16.6%) | -$26.54 M(+28.7%) |
| Mar 2024 | - | -$7.01 M(+18.1%) | -$20.63 M(+88.5%) |
| Dec 2023 | -$10.94 M(-220.7%) | -$5.94 M(+9.6%) | -$10.94 M(-578.7%) |
| Sep 2023 | - | -$5.42 M(+139.1%) | $2.29 M(-81.4%) |
| Jun 2023 | - | -$2.27 M(-184.7%) | $12.29 M(-34.3%) |
| Mar 2023 | - | $2.67 M(-63.3%) | $18.70 M(+106.4%) |
| Dec 2022 | $9.06 M(-79.9%) | $7.29 M(+59.0%) | $9.06 M(-18.4%) |
| Sep 2022 | - | $4.59 M(+10.5%) | $11.11 M(-38.4%) |
| Jun 2022 | - | $4.15 M(-159.6%) | $18.05 M(-33.1%) |
| Mar 2022 | - | -$6.97 M(-174.6%) | $26.98 M(-40.0%) |
| Dec 2021 | $45.01 M(+49.5%) | $9.34 M(-19.0%) | $45.01 M(-3.9%) |
| Sep 2021 | - | $11.53 M(-11.9%) | $46.83 M(+7.0%) |
| Jun 2021 | - | $13.08 M(+18.3%) | $43.76 M(+7.9%) |
| Mar 2021 | - | $11.06 M(-1.0%) | $40.56 M(+34.7%) |
| Dec 2020 | $30.10 M(+17.1%) | $11.16 M(+32.0%) | $30.10 M(+25.9%) |
| Sep 2020 | - | $8.46 M(-14.4%) | $23.92 M(-11.2%) |
| Jun 2020 | - | $9.88 M(+1558.2%) | $26.94 M(-2.6%) |
| Mar 2020 | - | $596.00 K(-88.0%) | $27.67 M(+7.7%) |
| Dec 2019 | $25.70 M(+4.1%) | $4.98 M(-56.7%) | $25.70 M(-16.1%) |
| Sep 2019 | - | $11.48 M(+8.2%) | $30.63 M(+17.2%) |
| Jun 2019 | - | $10.61 M(-871.9%) | $26.12 M(+29.5%) |
| Mar 2019 | - | -$1.38 M(-113.9%) | $20.18 M(-18.3%) |
| Dec 2018 | $24.69 M(-277.4%) | $9.90 M(+41.8%) | $24.69 M(+84.1%) |
| Sep 2018 | - | $6.98 M(+49.6%) | $13.41 M(+487.5%) |
| Jun 2018 | - | $4.67 M(+48.5%) | $2.28 M(-163.9%) |
| Mar 2018 | - | $3.14 M(-327.9%) | -$3.57 M(-74.3%) |
| Dec 2017 | -$13.92 M(+107.7%) | -$1.38 M(-66.8%) | -$13.92 M(+28.8%) |
| Sep 2017 | - | -$4.15 M(+248.9%) | -$10.81 M(+160.4%) |
| Jun 2017 | - | -$1.19 M(-83.5%) | -$4.15 M(-9.6%) |
| Mar 2017 | - | -$7.20 M(-515.8%) | -$4.59 M(-31.5%) |
| Dec 2016 | -$6.70 M(-74.8%) | $1.73 M(-31.0%) | -$6.70 M(-66.9%) |
| Sep 2016 | - | $2.51 M(-253.8%) | -$20.22 M(-30.7%) |
| Jun 2016 | - | -$1.63 M(-82.5%) | -$29.17 M(-2.5%) |
| Mar 2016 | - | -$9.31 M(-21.0%) | -$29.93 M(+12.4%) |
| Dec 2015 | -$26.63 M(-51.4%) | -$11.79 M(+83.0%) | -$26.63 M(+20.5%) |
| Sep 2015 | - | -$6.44 M(+169.2%) | -$22.10 M(+34.4%) |
| Jun 2015 | - | -$2.39 M(-60.2%) | -$16.43 M(-52.9%) |
| Mar 2015 | - | -$6.01 M(-17.2%) | -$34.89 M(-36.3%) |
| Dec 2014 | -$54.77 M | -$7.25 M(+829.9%) | -$54.77 M(-0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2014 | - | -$780.00 K(-96.3%) | -$54.82 M(-7.1%) |
| Jun 2014 | - | -$20.85 M(-19.5%) | -$58.99 M(+43.6%) |
| Mar 2014 | - | -$25.89 M(+254.5%) | -$41.07 M(+113.1%) |
| Dec 2013 | -$19.27 M(-28.8%) | -$7.30 M(+47.7%) | -$19.27 M(+2.1%) |
| Sep 2013 | - | -$4.95 M(+68.4%) | -$18.87 M(+0.2%) |
| Jun 2013 | - | -$2.94 M(-28.2%) | -$18.84 M(-19.9%) |
| Mar 2013 | - | -$4.09 M(-40.7%) | -$23.52 M(-13.0%) |
| Dec 2012 | -$27.05 M(+209.4%) | -$6.90 M(+40.4%) | -$27.05 M(+6.1%) |
| Sep 2012 | - | -$4.91 M(-35.5%) | -$25.50 M(+9.2%) |
| Jun 2012 | - | -$7.62 M(+0.0%) | -$23.35 M(+38.9%) |
| Mar 2012 | - | -$7.62 M(+42.5%) | -$16.81 M(+92.3%) |
| Dec 2011 | -$8.74 M(-181.9%) | -$5.35 M(+93.0%) | -$8.74 M(+306.5%) |
| Sep 2011 | - | -$2.77 M(+156.5%) | -$2.15 M(-218.3%) |
| Jun 2011 | - | -$1.08 M(-338.4%) | $1.82 M(-59.7%) |
| Mar 2011 | - | $453.00 K(-63.6%) | $4.51 M(-57.7%) |
| Dec 2010 | $10.67 M(-130.9%) | $1.25 M(+3.9%) | $10.67 M(+1534.1%) |
| Sep 2010 | - | $1.20 M(-25.7%) | $652.90 K(-108.4%) |
| Jun 2010 | - | $1.61 M(-75.6%) | -$7.80 M(-63.7%) |
| Mar 2010 | - | $6.61 M(-175.4%) | -$21.48 M(-37.8%) |
| Dec 2009 | -$34.52 M(-34.0%) | -$8.77 M(+20.9%) | -$34.52 M(+3.7%) |
| Sep 2009 | - | -$7.25 M(-39.9%) | -$33.28 M(-10.2%) |
| Jun 2009 | - | -$12.07 M(+87.5%) | -$37.08 M(-4.5%) |
| Mar 2009 | - | -$6.43 M(-14.5%) | -$38.81 M(-25.8%) |
| Dec 2008 | -$52.31 M(-28.8%) | -$7.53 M(-31.9%) | -$52.31 M(-13.9%) |
| Sep 2008 | - | -$11.05 M(-19.9%) | -$60.73 M(-16.9%) |
| Jun 2008 | - | -$13.80 M(-30.8%) | -$73.05 M(-4.8%) |
| Mar 2008 | - | -$19.94 M(+25.1%) | -$76.75 M(+4.4%) |
| Dec 2007 | -$73.49 M(+12.8%) | -$15.94 M(-31.8%) | -$73.49 M(+5.3%) |
| Sep 2007 | - | -$23.37 M(+33.5%) | -$69.79 M(+18.1%) |
| Jun 2007 | - | -$17.50 M(+4.9%) | -$59.08 M(-7.0%) |
| Mar 2007 | - | -$16.68 M(+36.2%) | -$63.52 M(-2.5%) |
| Dec 2006 | -$65.13 M(+172.9%) | -$12.25 M(-3.2%) | -$65.13 M(+8.9%) |
| Sep 2006 | - | -$12.66 M(-42.3%) | -$59.84 M(+13.3%) |
| Jun 2006 | - | -$21.94 M(+19.9%) | -$52.83 M(+45.4%) |
| Mar 2006 | - | -$18.29 M(+163.2%) | -$36.33 M(+52.3%) |
| Dec 2005 | -$23.86 M(+160.7%) | -$6.95 M(+23.0%) | -$23.86 M(+41.1%) |
| Sep 2005 | - | -$5.65 M(+3.9%) | -$16.91 M(+50.2%) |
| Jun 2005 | - | -$5.44 M(-6.7%) | -$11.26 M(+93.3%) |
| Mar 2005 | - | -$5.82 M | -$5.82 M |
| Dec 2004 | -$9.15 M | - | - |
FAQ
- What is Vanda Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual EBITDA year-on-year change?
- What is Vanda Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Vanda Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals TTM EBITDA year-on-year change?
What is Vanda Pharmaceuticals annual EBITDA?
The current annual EBITDA of VNDA is -$10.94 M
What is the all time high annual EBITDA for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual EBITDA is $45.01 M
What is Vanda Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, VNDA annual EBITDA has changed by -$20.00 M (-220.75%)
What is Vanda Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of VNDA is -$9.03 M
What is the all time high quarterly EBITDA for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly EBITDA is $13.08 M
What is Vanda Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, VNDA quarterly EBITDA has changed by -$2.02 M (-28.84%)
What is Vanda Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of VNDA is -$30.16 M
What is the all time high TTM EBITDA for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high TTM EBITDA is $46.83 M
What is Vanda Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, VNDA TTM EBITDA has changed by -$9.53 M (-46.21%)